Quality of Life in Mild Cognitive Impairment and Mild Dementia Associated with Alzheimer’s Disease: A Systematic Review DOI Creative Commons

Joanna Campbell,

Louis Lavoie,

Mariana Farraia

и другие.

Neurology and Therapy, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 3, 2024

Mild cognitive impairment (MCI) and Alzheimer's disease (AD) have a profound impact on patients' quality of life (QoL), with progressive declines occurring as the advances. This systematic review aims to summarize published evidence patient-reported outcomes (PROs) in individuals MCI due AD mild dementia. Comprehensive searches were conducted across five major databases identify studies reporting utility values, disutilities, QoL measures these patient populations. A total 23 included that utilized various assessment tools, including EQ-5D (n = 14), SF-36/SF-12 4), QOL-AD 11). Reported scores ranged from 0.81 0.92 for patients 0.67 0.85 those AD, indicating noticeable decline progresses. 33.8 42.5 32.4 38.1 equally reflecting greater advancement. Interventions generally associated smaller PROs compared placebo, suggesting positive treatment mitigating deterioration. The findings underscore significant differences between emphasizing potential benefit early intervention preserve delay progression. highlights importance continued research better understand dementia, particularly terms capturing comprehensive evaluating effectiveness interventions over time. These can contribute more informed approach clinical practice support decision-making management early-stage AD.

Язык: Английский

Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence DOI Creative Commons
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes

и другие.

Receptors, Год журнала: 2025, Номер 4(1), С. 2 - 2

Опубликована: Янв. 26, 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including dulaglutide, liraglutide, semaglutide, and exenatide, are effective treatments for type 2 diabetes mellitus (T2DM) obesity. These agents mimic the action of endogenous incretin glucagon-like (GLP-1) by enhancing insulin secretion, inhibiting glucagon release, promoting weight loss through appetite suppression. GLP-1RAs have recently been suggested to neuroprotective effects, suggesting their potential as treatment neurodegenerative disorders, such Alzheimer’s disease (AD). AD T2DM share several common pathophysiological mechanisms, resistance, chronic inflammation, oxidative stress, mitochondrial dysfunction. shared mechanisms suggest that therapeutic targeting metabolic dysfunction may also be beneficial conditions. Preclinical studies on in models, both vitro vivo, demonstrated promising reductions amyloid-beta accumulation, decreased tau hyperphosphorylation, improved synaptic plasticity, enhanced neuronal survival. Despite encouraging results from preclinical challenges need addressed before can widely used treatment. Ongoing clinical trials investigating cognitive benefits patients, aiming establish role a option AD. This review aimed examine current literature GLP-1

Язык: Английский

Процитировано

1
FLIM-Phasor Analysis (FLIM-ϕ) of Aβ-Induced Membrane Order Alterations: Towards a Cell-Based Biosensor for Early Alzheimer’s Disease Diagnosis DOI Creative Commons
Antonella Battisti, María Grazia Ortore, Silvia Vilasi

и другие.

Micromachines, Год журнала: 2025, Номер 16(2), С. 234 - 234

Опубликована: Фев. 19, 2025

Alzheimer's disease (AD) is a progressive neurodegenerative disorder, and its early detection can be critical for prompt intervention that potentially slow down the progression improve patient's quality of life. However, diagnosis based solely on clinical symptoms challenging, especially in stages, while specific biomarkers such as amyloid-β peptide (Aβ) tau proteins provide objective evidence diagnosis. In this work, we explored effects Aβ cell membrane properties thanks to fluorescence lifetime imaging (FLIM) combined with phasor analysis (FLIM-ϕ). The results showed viscosity altered by presence cells experience effect even at nanomolar concentrations peptide. This considerable sensitivity opens up possibility envisioning cell-based biosensor able detect very low biological fluid, thus enabling timely intervention.

Язык: Английский

Процитировано

0
Efficient regularized estimation of graphical proportional hazards model with interval-censored data DOI
Huimin Lu, Yilong Wang,

Heming Bing

и другие.

Computational Statistics & Data Analysis, Год журнала: 2025, Номер unknown, С. 108178 - 108178

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Quality of Life in Mild Cognitive Impairment and Mild Dementia Associated with Alzheimer’s Disease: A Systematic Review DOI Creative Commons

Joanna Campbell,

Louis Lavoie,

Mariana Farraia

и другие.

Neurology and Therapy, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 3, 2024

Mild cognitive impairment (MCI) and Alzheimer's disease (AD) have a profound impact on patients' quality of life (QoL), with progressive declines occurring as the advances. This systematic review aims to summarize published evidence patient-reported outcomes (PROs) in individuals MCI due AD mild dementia. Comprehensive searches were conducted across five major databases identify studies reporting utility values, disutilities, QoL measures these patient populations. A total 23 included that utilized various assessment tools, including EQ-5D (n = 14), SF-36/SF-12 4), QOL-AD 11). Reported scores ranged from 0.81 0.92 for patients 0.67 0.85 those AD, indicating noticeable decline progresses. 33.8 42.5 32.4 38.1 equally reflecting greater advancement. Interventions generally associated smaller PROs compared placebo, suggesting positive treatment mitigating deterioration. The findings underscore significant differences between emphasizing potential benefit early intervention preserve delay progression. highlights importance continued research better understand dementia, particularly terms capturing comprehensive evaluating effectiveness interventions over time. These can contribute more informed approach clinical practice support decision-making management early-stage AD.

Язык: Английский

Процитировано

1